Characterisation of a New Poor-Risk Sub-Category of Chronic Phase Chronic Myeloid Leukaemia

慢性期慢性粒细胞白血病新的低风险亚类的特征

• 批准号: nhmrc : 1026932
• 负责人: Prof Deborah White
• 金额: $ 40.63万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/characterisation-new-poor-myeloid-leukaemia/110527
• 关键词: Characterisation; New; Poor; Risk; Sub

The introduction of targeted therapy for chronic myeloid leukaemia (CML) has resulted in excellent responses for many patients. However, some 30-40% of patients respond very poorly to this therapy and therapeutic advances are urgently needed to improve response in these patients. In order to better treat these poor risk patients we aim, in this project, to develop a greater understanding of their disease, and from this identify specific cellular targets for future drug treatment/combination therapy.

引入针对慢性髓样白血病（CML）的靶向疗法对许多患者产生了出色的反应。但是，大约30-40％的患者对这种疗法的反应较差，并且迫切需要治疗进展来改善这些患者的反应。为了更好地治疗这些危险患者，我们在该项目中的目标是对他们的疾病有了更大的了解，并从该项目中确定了未来药物治疗/联合疗法的特定细胞靶标。